213 results
The British journal of dermatology,
13 2 2023, Pages ljad159
Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, Kamsteeg M, Haeck I, Oosting AJ, van Lumig PPM, van Lynden-van Nes AMT, Tupker RA, Flinterman A, Garritsen FM, Touwslager WRH, de Bruin-Weller MS, Schuttelaar ML, de Graaf M
Background: Limited data is available regarding patient-centered dosing of dupilumab for atopic dermatitis (AD) in daily practice. Objectives: To evaluate our patient-centered dupilumab dosing regimen in daily practice, to assess prognostic factors for successful tapering and to estimate medication-related cost savings. Methods: This prospective multicenter study included adult AD patients, participating in the BioDay registry, treated with dupilumab for ≥1.3 years. Interval prolongation was con...
Abstract
Frontiers in pharmacology,
Volume 14, 27 4 2023, Pages 1098184
Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy.
Buijsers B, Garsen M, de Graaf M, Bakker-van Bebber M, Guo C, Li X, van der Vlag J
Introduction: The endothelial glycocalyx degrading enzyme heparanase-1 (HPSE1) is a major contributor to kidney diseases, such as glomerulonephritis and diabetic nephropathy. Therefore, inhibition of HPSE1 could be an interesting therapeutic strategy to treat glomerular diseases. A possible HPSE1 inhibitor is heparanase-2 (HPSE2) because HPSE2 is a structural homolog of HPSE1 without enzymatic activity. The importance of HPSE2 has been recently demonstrated in HPSE2-deficient mice, since these m...
Abstract
The Science of the total environment,
Volume 883, 25 4 2023, Pages 163599
Capturing the SARS-CoV-2 infection pyramid within the municipality of Rotterdam using longitudinal sewage surveillance.
de Graaf M, Langeveld J, Post J, Carrizosa C, Franz E, Izquierdo-Lara RW, Elsinga G, Heijnen L, Been F, van Beek J, Schilperoort R, Vriend R, Fanoy E, de Schepper EIT, Koopmans MPG, Medema G
Despite high vaccination rates in the Netherlands, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate. Longitudinal sewage surveillance was implemented along with the notification of cases as two parts of the surveillance pyramid to validate the use of sewage for surveillance, as an early warning tool, and to measure the effect of interventions. Sewage samples were collected from nine neighborhoods between September 2020 and November 2021. Comparative analysis an...
Abstract
Musculoskeletal science & practice,
Volume 65, 14 2 2023, Pages 102764
Comparison between two patient-reported outcome measures for patients with cervical radiculopathy: A think-aloud study.
Thoomes E, de Graaf M, Gallina A, Falla D, Stathi A
Background: The Cervical Radiculopathy Impact Scale (CRIS) and Patient Specific Functional Scale 2.0 (PSFS 2.0) are patient-reported outcome measures (PROMs) used to assess activity limitations in patients with cervical radiculopathy (CR). This study a) compared the CRIS subscale 3 and the PSFS 2.0 in patients with CR with respect to completeness and patient preference, b) established the correlation between both PROMs in assessing the individual patient's level of functional limitations an...
Abstract
The British journal of dermatology,
22 4 2023, Pages ljad085
Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
Ragamin A, Tupker RA, de Graaf M, Rustemeyer T, Pasmans SGMA, Schappin R, Schuttelaar MLA
Abstract
Allergy,
19 3 2023
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
Background: Dupilumab-associated ocular surface disease (DAOSD) is frequently reported as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to investigate the frequency and severity of DAOSD, ophthalmic treatment response and to learn more about the effect of dupilumab on conjunctival goblet cells (GC). Methods: This prospective study included dupilumab-treated AD patients between February 2020 and June 2022 from the University Medical Centre Utrecht. Patients...
Abstract
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Volume 53, Issue 5, 16 3 2023, Pages 586-589
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.
Achten R, Dekkers C, Bakker D, van Luijk C, de Graaf M, van Wijk F, de Boer J, de Bruin-Weller M, Thijs J
Abstract
Journal of cardiovascular computed tomography,
13 2 2023, Pages S1934-5925(23)00067-9
Plaque volume, composition, and fraction versus ischemia and outcomes in patients with coronary artery disease.
Kuneman JH, van den Hoogen IJ, Schultz J, Maaniitty T, van Rosendael AR, Kamperidis V, de Graaf MA, Broersen A, Jukema JW, Bax JJ, Saraste A, Knuuti J
Background: The various plaque components have been associated with ischemia and outcomes in patients with coronary artery disease (CAD). The main goal of this analysis was to test the hypothesis that, at patient level, the fraction of non-calcified plaque volume (PV) of total PV is associated with ischemia and outcomes in patients with CAD. This ratio could be a simple and clinically useful parameter, if predicting outcomes. Methods: Consecutive patients with suspected CAD undergoing coronary c...
Abstract
Acta dermato-venereologica,
Volume 103, 8 2 2023, Pages adv00881
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
Achten R, Van der Rijst L, Piena M, Lamers H, De Beer F, De Bruin-Weller M, De Graaf M
Data concerning the economic and humanistic burden in patients with paediatric atopic dermatitis (AD) and their families are scarce. This retrospective study investigated these burdens in paediatric patients with AD using maintenance treatment with topical corticosteroids and/or conventional systemic immunosuppressants. Patient-reported outcomes regarding quality of life, AD severity, and parental work-related impairment were completed at inclusion. Data on healthcare resource utilization and me...
Abstract
EBioMedicine,
Volume 90, 6 1 2023, Pages 104506
Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria.
Garsen M, Buijsers B, Sol M, Gockeln L, Sonneveld R, van Kuppevelt TH, de Graaf M, van den Born J, Kamps JAAM, van Raalte DH, van der Meer RW, Lamb HJ, Hillebrands JL, Rabelink TJ, Maciej-Hulme ML, Krenning G, Nijenhuis T, van der Vlag J
Background: Proteinuria is associated with many glomerular diseases and a risk factor for the progression to renal failure. We previously showed that heparanase (HPSE) is essential for the development of proteinuria, whereas peroxisome proliferator-activated receptor ɣ (PPARɣ) agonists can ameliorate proteinuria. Since a recent study showed that PPARɣ regulates HPSE expression in liver cancer cells, we hypothesized that PPARɣ agonists exert their reno-protective effect by inhibiting glomerular H...
Abstract
Ocular immunology and inflammation,
28 4 2023, Pages 1-5
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile.
Achten R, van Luijk C, Thijs J, Drylewicz J, Delemarre E, Nierkens S, Bakker D, van Wijk F, de Graaf M, de Bruin-Weller M, de Boer J, Kuiper J
Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab treatment and to compare the proteomic profile of aqueous humor (AqH) of dupilumab-associated uveitis (n=3/5 available samples) with non-infectious uveitis (n=27) and cataract controls (n=11). Included patients were treated at the University Medical Center Utr...
Abstract
American heart journal plus : cardiology research and practice,
Volume 27, 23 4 2023, Pages 100280
Coronary calcium score in COVID-19 survivors: Association with cardiac injury and cardiac function after 6 weeks.
Groen RA, de Graaf MA, Stöger JL, van Dijkman PRM, Jukema JW, Schalij MJ, Geelhoed JJM, Antoni ML
Aims: Cardiac manifestations are common in COVID-19, often elevated serum troponin levels or myocardial dysfunction on trans-thoracic echocardiography (TTE) is observed. Both parameters are associated with increased in-hospital mortality. Possibly, subclinical coronary atherosclerosis plays a role, of which severity can be assessed by calculating the coronary artery calcium (CAC) score. This study aims to determine the relation between coronary atherosclerosis and cardiac manifestations in COVID...
Abstract
JAAD international,
Volume 11, 18 3 2023, Pages 137-139
Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health.
Hermans MM, Pasmans SGMA, de Laat PCJ, Slieker MG, Mendels EJ, de Graaf M, Langeveld HR, Schappin R, Rietman AB, Breugem CC, Breur JMPJ, de Wildt SN, Raphael MF
Abstract
Acta dermato-venereologica,
Volume 103, 16 3 2023, Pages adv00872
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, Kamsteeg M, De Graaf M, De Bruin-Weller MS
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay...
Abstract
The Science of the total environment,
Volume 873, 14 2 2023, Pages 162209
Rise and fall of SARS-CoV-2 variants in Rotterdam: Comparison of wastewater and clinical surveillance.
Izquierdo-Lara RW, Heijnen L, Oude Munnink BB, Schapendonk CME, Elsinga G, Langeveld J, Post J, Prasad DK, Carrizosa C, Been F, van Beek J, Schilperoort R, Vriend R, Fanoy E, de Schepper EIT, Sikkema RS, Molenkamp R, Aarestrup FM, Medema G, Koopmans MPG, de Graaf M
Monitoring of SARS-CoV-2 in wastewater (WW) is a promising tool for epidemiological surveillance, correlating not only viral RNA levels with the infection dynamics within the population, but also to viral diversity. However, the complex mixture of viral lineages in WW samples makes tracking of specific variants or lineages circulating in the population a challenging task. We sequenced sewage samples of 9 WW-catchment areas within the city of Rotterdam, used specific signature mutations from indi...
Abstract
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Volume 53, Issue 5, 13 2 2023, Pages 582-585
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Boesjes CM, van Emst M, Bakker DS, Spekhorst LS, van Wijk F, de Graaf M, de Bruin-Weller MS
Abstract
Clinical and translational allergy,
Volume 13, Issue 1, 1 1 2023, Pages e12221
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease.
Achten R, Thijs J, van der Wal M, van Luijk C, van Luin M, El Amrani M, Knol E, Delemarre E, Jager CDH, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
Background: The patho-mechanism of ocular surface disease (OSD) in dupilumab-treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients. Methods: This prospective study included dupilumab-treated moderate-to-severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and afte...
Abstract
Clinical and translational allergy,
Volume 13, Issue 1, 1 1 2023, Pages e12219
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis.
Spekhorst LS, de Graaf M, van der Rijst LP, Zuithoff NPA, Schweizer RC, Kamsteeg M, Haeck I, van Lynden-van Nes AMT, van Lumig P, Romeijn GLE, Schuttelaar ML, de Bruin-Weller MS
Abstract
Cited 1 times since 2022 (2.3 per year)
source: EuropePMC
The Science of the total environment,
Volume 865, 26 4 2022, Pages 161196
Normalisation of SARS-CoV-2 concentrations in wastewater: The use of flow, electrical conductivity and crAssphage.
Langeveld J, Schilperoort R, Heijnen L, Elsinga G, Schapendonk CEM, Fanoy E, de Schepper EIT, Koopmans MPG, de Graaf M, Medema G
Over the course of the Corona Virus Disease-19 (COVID-19) pandemic in 2020-2022, monitoring of the severe acute respiratory syndrome coronavirus 2 ribonucleic acid (SARS-CoV-2 RNA) in wastewater has rapidly evolved into a supplementary surveillance instrument for public health. Short term trends (2 weeks) are used as a basis for policy and decision making on measures for dealing with the pandemic. Normalisation is required to account for the dilution rate of the domestic wastewater that can stro...
Abstract
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Volume 53, Issue 2, 22 4 2022, Pages 239-243
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
Achten R, Thijs J, van Luijk C, Knol E, Delemarre E, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
Abstract
